Abstract: Ovarian hyperstimulation syndrome (OHSS) is a common iatrogenic complication with potential risk in assisted reproductive technology, which can endanger life in severe cases. At present, the pathogensis is not clear. Prevention is the main clinical method, so the early detection is crucial. Due to OHSS is a self-limiting disease, timely diagnosis, treatment and follow-up visit are very important. However, there is no gold standard of OHSS prediction. We report an OHSS patient with the increased level of CA125 who undergo the IVF-ET treatment in this paper. With literature review, we therefore explore the correlation, and its clinical significance, between serum CA125 and OHSS, and discuss whether CA125 can be used as an OHSS parameter of risk evaluation, symptomatic treatment and follow-up visit.

Key words: Ovarian hyperstimulation syndrome, Fertilization in vitro, Embryo transfer, CA-125 antigen, Case reports